Gland Pharma Ltd. (IN:GLAND)

:GLAND

GLAND

Gland Pharma Ltd.

RESEARCH TOOLSreports

Want to see IN:GLAND full AI Analyst Report?

Gland Pharma Ltd. (GLAND) Price & Analysis

1 Followers

GLAND Stock Chart & Stats

₹1713.95

-₹19.65(-1.06%)

At close: Jan 09 4:00 PM EST

₹1713.95

-₹19.65(-1.06%)

Day’s Range― - ―

52-Week Range₹1,575.00 - ₹2,395.00

Previous CloseN/A

Volume93.91K

Average Volume (3M)9.08K

Market Cap

₹379.85B

Enterprise Value₹339.95B

Total Cash (Recent Filing)₹27.04B

Total Debt (Recent Filing)₹3.02B

Price to Earnings (P/E)37.0

Beta0.66

Next Earnings

Aug 11, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend Yield1.07%

Share Statistics

EPS (TTM)47.97

Shares Outstanding164,756,420

10 Day Avg. Volume10,062

30 Day Avg. Volume9,084

Financial Highlights & Ratios

PEG Ratio0.58

Price to Book (P/B)2.70

Price to Sales (P/S)4.35

P/FCF Ratio37.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,080.00

Price Target Upside21.36% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)74.51

Revenue Forecast (FY)₹73.47B

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthExtremely low leverage and a large equity base give Gland durable financial flexibility. This reduces refinancing and solvency risk, supports capex for sterile capacity and R&D, and allows the company to absorb shocks or pursue strategic investments without jeopardizing operations over the next several quarters.

Improving Cash GenerationA marked rise in operating cash flow and an ~85% jump in free cash flow signal stronger internal funding for growth and maintenance. Improved cash generation enhances the firm's ability to fund capacity, support contract manufacturing commitments, and provide financial resilience versus relying on external financing.

CDMO / Sterile Injectables FocusSpecialization in sterile and complex injectables addresses high-barrier, regulated niches with steady hospital demand. CDMO exposure creates multi-year revenue visibility from contracts and regulatory dossiers across markets, underpinning a defensible business model and structural demand resilience.

Bears Say

Gross Margin VolatilityA dramatic drop in gross margin points to structural pressure from cost increases, product-mix shifts, or pricing erosion. Sustained lower gross margins would weaken operating leverage, compress EBITDA and net margins, and impair the firm's ability to sustainably generate high returns and finance growth internally.

Profitability Below Prior PeakEarnings not recovering to FY2022 peaks despite revenue growth implies margin deterioration or one-off drains. Persistently lower profitability limits return on equity and free cash available for reinvestment or shareholder distributions, raising questions about durable earnings quality.

Moderate Cash ConversionCash conversion below EBITDA and FCF at ~60% of net income suggests working capital or capex consumption reduces cash that earnings imply. This inconsistent conversion constrains the firm's ability to reliably self-fund expansion, smooth dividends, or rapidly de-lever during downturns.

Gland Pharma Ltd. News

Gland Pharma Seeks Shareholder Nod to Reappoint Independent Director via E-Voting

An announcement from Gland Pharma Ltd. ( ($IN:GLAND) ) is now available. Gland Pharma has initiated a postal...

2M ago

GLAND

Gland Pharma Schedules Investor Meet Arranged by Goldman Sachs

Gland Pharma Ltd. ( ($IN:GLAND) ) just unveiled an update. Gland Pharma Limited has notified the stock exchanges...

4M ago

GLAND

Gland Pharma Schedules Series of Investor and Analyst Meetings in February 2026

Gland Pharma Ltd. ( ($IN:GLAND) ) just unveiled an announcement. Gland Pharma Limited has announced a series of...

4M ago

GLAND

Gland Pharma uploads Q3 FY26 earnings call recording for investors

An announcement from Gland Pharma Ltd. ( ($IN:GLAND) ) is now available. Gland Pharma Limited has notified the...

4M ago

GLAND

Gland Pharma Schedules Investor Meetings for November 2025

Gland Pharma Ltd. ( ($IN:GLAND) ) has shared an update. Gland Pharma Limited has announced a series of...

7M ago

GLAND

Gland Pharma Appoints New Secretarial Auditors to Strengthen Governance

Gland Pharma Ltd. ( ($IN:GLAND) ) has issued an announcement. Gland Pharma Limited has announced the appointment of...

10M ago

GLAND

Gland Pharma Updates RTA Contact Details Following Rebranding

Gland Pharma Ltd. ( ($IN:GLAND) ) just unveiled an announcement. Gland Pharma Limited has announced a change in...

1y ago

GLAND

Gland Pharma Receives SEBI Compliance Certificate for Q1 2025

An update from Gland Pharma Ltd. ( ($IN:GLAND) ) is now available. Gland Pharma Limited has announced the...

1y ago

GLAND

Gland Pharma Announces Trading Window Closure Ahead of Financial Results

Gland Pharma Ltd. ( ($IN:GLAND) ) has issued an update. Gland Pharma Limited has announced the closure of...

1y ago

GLAND

Gland Pharma Initiates Postal Ballot for Shareholder Approval

Gland Pharma Ltd. ( ($IN:GLAND) ) has provided an announcement. Gland Pharma Limited has announced the dispatch of...

1y ago

GLAND

GLAND FAQ

What was Gland Pharma Ltd.’s price range in the past 12 months?

Gland Pharma Ltd. lowest stock price was ₹1575.00 and its highest was ₹2395.00 in the past 12 months.

What is Gland Pharma Ltd.’s market cap?

Gland Pharma Ltd.’s market cap is ₹379.85B.

When is Gland Pharma Ltd.’s upcoming earnings report date?

Gland Pharma Ltd.’s upcoming earnings report date is Aug 11, 2026 which is in 60 days.

How were Gland Pharma Ltd.’s earnings last quarter?

Gland Pharma Ltd. released its earnings results on May 15, 2026. The company reported ₹22.3 earnings per share for the quarter, beating the consensus estimate of ₹16.252 by ₹6.048.

Is Gland Pharma Ltd. overvalued?

According to Wall Street analysts Gland Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gland Pharma Ltd. pay dividends?

Gland Pharma Ltd. pays a Notavailable dividend of ₹20 which represents an annual dividend yield of 1.07%. See more information on Gland Pharma Ltd. dividends here

What is Gland Pharma Ltd.’s EPS estimate?

Gland Pharma Ltd.’s EPS estimate is 17.

How many shares outstanding does Gland Pharma Ltd. have?

Gland Pharma Ltd. has 164,756,420 shares outstanding.

What happened to Gland Pharma Ltd.’s price movement after its last earnings report?

Gland Pharma Ltd. reported an EPS of ₹22.3 in its last earnings report, beating expectations of ₹16.252. Following the earnings report the stock price went down -1.48%.

Which hedge fund is a major shareholder of Gland Pharma Ltd.?

Currently, no hedge funds are holding shares in IN:GLAND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gland Pharma Ltd.

Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Gland Pharma Ltd. (GLAND) Earnings & Revenues

Historic Earnings Reports

GLAND Stock 12 Month Forecast

Average Price Target

₹2,080.00

▲(21.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1595":"₹1,595","1944":"₹1,944","2293":"₹2,293","1769.5":"₹1,769.5","2118.5":"₹2,118.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.08K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1595,1769.5,1944,2118.5,2293],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2292.5,2276.153846153846,2259.8076923076924,2243.4615384615386,2227.1153846153848,2210.769230769231,2194.423076923077,2178.076923076923,2161.730769230769,2145.3846153846152,2129.0384615384614,2112.6923076923076,2096.346153846154,{"y":2080,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2292.5,2276.153846153846,2259.8076923076924,2243.4615384615386,2227.1153846153848,2210.769230769231,2194.423076923077,2178.076923076923,2161.730769230769,2145.3846153846152,2129.0384615384614,2112.6923076923076,2096.346153846154,{"y":2080,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2292.5,2276.153846153846,2259.8076923076924,2243.4615384615386,2227.1153846153848,2210.769230769231,2194.423076923077,2178.076923076923,2161.730769230769,2145.3846153846152,2129.0384615384614,2112.6923076923076,2096.346153846154,{"y":2080,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1596.38,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1859.38,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1960.93,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1868.8,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1980.55,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1929.5,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1726.2,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1715.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1897.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1795.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1706.65,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1751,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2292.5,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >